Chiba University Team Maps Stress-to-Joint Inflammation Pathway in Mice

Blocking a single receptor — CXCR2, the docking point for the chemokine CXCL1 — significantly reduced stress-triggered arthritis in mice, according to a study published in Science Advances by a team at Chiba University working with Asahi General Hospital and International University of Health and Welfare Narita Hospital. The paper, titled "Fibroblast-like synoviocytes exacerbate autoimmune arthritis upon psychological stress in an IL-6–dependent manner," traces a concrete route from psychological stress to joint inflammation: brown adipose tissue releases interleukin-6 (IL-6), which drives synovial cells to recruit neutrophils.

The finding addresses a long-standing clinical puzzle. Rheumatoid arthritis (RA) patients often report flares under psychological stress, and the association has been documented for decades, but the molecular mechanism — particularly how stress can reignite inflammation in joints that have entered remission — has remained unclear.

What did the experiments measure?

The researchers used an antigen-induced arthritis (AIA) mouse model. They let the arthritis enter a remission-like state, then exposed the animals to restraint stress. Stress reactivated inflammation in the joints.

Tissue analysis, immune-cell profiling and molecular measurements traced the signal chain:

• Stress activated the sympathetic nervous system and brown adipose tissue (BAT), a fat type involved in heat production.
• Activated BAT released IL-6, an inflammatory signaling protein, into circulation.
• IL-6 stimulated fibroblast-like synoviocytes (FLS), specialized cells in the synovial tissue surrounding joints, to produce CXCL1, a chemokine that attracts neutrophils.
• Neutrophil recruitment reactivated joint inflammation.

"Our findings suggest that the effects of psychological stress on arthritis extend beyond the immune cells traditionally associated with autoimmune disease. Instead, stress can activate processes within other tissues that contribute to the return of joint inflammation," said study co-lead assistant professor Shigeru Tanaka of Chiba University Graduate School of Medicine.

Which intervention points did the team test?

The researchers blocked key receptors and monitored inflammatory markers, joint swelling and immune-cell accumulation. Treatment with a β3-adrenergic receptor antagonist reduced plasma IL-6 levels, joint swelling, CXCL1 expression and neutrophil accumulation in the joints.

"Our current research revealed that β3-adrenergic receptor blockade successfully suppresses stress-induced arthritis flares," they wrote. "This finding suggests a possible therapeutic strategy targeting the sympathetic nervous system."

Blocking the CXCR2 receptor, which responds to CXCL1, also significantly reduced stress-triggered arthritis in the model.

The mechanism operates independently of lymphocytes, the immune cells usually implicated in autoimmune disease. "Our study demonstrated a phenomenon in which IL-6 originates from outside the joint and stimulates FLS, leading to the recurrence of arthritis," the investigators explained, noting that within the RA joint, macrophages and FLS also produce IL-6, forming a local inflammatory network.

What did the human data show?

The team examined whether the stress pathway appears in RA patients. Carriers of Trp64Arg, a variant of the ADRB3 gene that makes cells less responsive to stress-related hormones, showed a weaker link between perceived stress and arthritis activity than patients without the variant.

That analysis was observational, however, and the authors state it does not prove stress directly caused changes in disease activity. The mouse work, not the human association, carries the mechanistic weight of the paper.

What could this mean for RA portfolios?

For R&D managers, the study identifies a defined axis — BAT, IL-6, fibroblast — as a candidate target. "Our findings suggest that targeting the stress-responsive pathways may offer a future therapeutic strategy that acts without broadly suppressing the immune system," said research co-lead professor Hiroshi Nakajima, MD, PhD, senior and co-corresponding author at the Graduate School of Medicine.

The distinction matters: existing RA biologics broadly dampen immune activity. A pathway acting on stress-responsive tissue signals could complement them without systemic immune suppression.

The authors conclude that the findings "identify a BAT–IL-6–fibroblast axis that reactivates inflammatory memory in arthritis and suggest that targeting stress-responsive pathways may provide a complementary therapeutic strategy alongside current RA treatments without broadly suppressing systemic immunity." Whether the mouse mechanism and the β3-adrenergic and CXCR2 blockade results translate to patients will require controlled human studies.